Four molecular subtypes of colorectal cancer and their precursor lesions

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 6, 2011, Pages 698-703

  Kang, Gyeong Hoon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; AGED; ARTICLE; COLORECTAL TUMOR; CPG ISLAND; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; KOREA; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; MUTATION; PRECANCER; SURVIVAL RATE;

ADENOCARCINOMA; ADENOMA; AGED; COLORECTAL NEOPLASMS; CPG ISLANDS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KOREA; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958806016     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002; 99(6):3740-3745. (Pubitemid 34252176)
2. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A. 2006; 103(5):1412-1417. (Pubitemid 43191179)
3. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006,38(12):1378-1385. (Pubitemid 44837559)
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-428. (Pubitemid 34587077)
5. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005; 14(suppl 1):R65R76.
6. Park SY, Kim BH, Kim JH, et al. Methylation profiles of CpG island loci in major types of human cancers.; Korean Med Sei. 2007; 22(2):311-317.
7. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-3229. (Pubitemid 32695003)
8. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24(2):132-138. (Pubitemid 30094712)
9. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4):536-540. (Pubitemid 24308343)
10. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007; 3(9): 1709-1723. (Pubitemid 47510263)
11. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006; 38(2):149153.
12. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-1113. (Pubitemid 350134889)
13. Samowitz WS. Genetic and epigenetic changes in colon cancer. Exp Mol Pathol. 2008; 85(1):64-67.
14. Nosho K, lrahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008,3(11) :e3698. doi:10.1371/journal. pone.0003698.
15. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6):2073-2087.
16. Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001; 48(6):821829.
17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. ) Clin Oncol. 2005; 23(3):609-618. (Pubitemid 46224239)
18. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001; 158(4):1517-1524. (Pubitemid 32281315)
19. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001; 10(9):917-923. (Pubitemid 32844897)
20. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138(6):2059-2072.
21. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010; 138(6):2088-2100.
22. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10(1):13-27. (Pubitemid 351184831)
23. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999; 96(15):8681-8686. (Pubitemid 29354851)
24. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000; 97(2):710-715. (Pubitemid 30070374)
25. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005; 129(3):837-845. (Pubitemid 41242676)
26. Bariol C, Suter C, Cheong K, et al. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol. 2003; 162(4):1361-1371. (Pubitemid 36350680)
27. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, lacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002; 51(6):797-802. (Pubitemid 35408598)
28. Lee S, Cho NY, Choi M, Yoo E), Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008; 58(2): 104-113.
29. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009; 455(6):485-494.
30. Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008; 17(11):3208-3215.
31. Chan AO, lssa JP, Morris JS, Hamilton SR, Rashid A. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 2002; 160(2):529-536. (Pubitemid 34160330)
32. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38(7):787-793. (Pubitemid 43980599)
33. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.; Mol Diagn. 2007;9(3):305-314. (Pubitemid 47305066)
34. Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008; 132(10):16571665.
35. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003; 21(20):3729-3736. (Pubitemid 46606226)
36. Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008; 68(20):8541-8546.
37. Shen L, Catalano PJ, Benson AB III, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007; 13(20):6093-6098.
38. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002; 122(5): 1376-1387. (Pubitemid 34465180)
39. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003,348(10):919-932. (Pubitemid 36298000)
40. Zhang YZ, Sheng JQ, Li SR, Zhang H. Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population. World J Gastroenterol. 2005; 11(10):1481-1488. (Pubitemid 40468083)
41. Fujita S, Moriya Y, Sugihara K, Akasu T, Ushio K. Prognosis of hereditary nonpolyposis colorectal cancer (HNPCC) and the role of Japanese criteria for HNPCC. Jpn J Clin Oncol. 1996; 26(5):351-355. (Pubitemid 126470695)
42. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008; 26(35): 5783-5788.
43. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007; 104(47):18654-18659. (Pubitemid 350210752)
44. Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010; 16(1) :21-33.
45. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002; 62(22):6451-6455. (Pubitemid 35364105)
46. Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006; 118(7): 1721 -172 7.
47. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004; 25(4):527-533. (Pubitemid 38528645)
48. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14):6063-6069.
49. Nagasaka T, Sasamoto H, Notohara K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004; 22(22):4584-4594. (Pubitemid 41185126)
50. Cheng YW, Pineas H, Bacolod MD, et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008; 14(19):6005-6013.
51. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010; 56(2): 167-179.
52. Watanabe T, Kobunai T, Toda E, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006; 66(20):9804-9808. (Pubitemid 44672030)
53. Day DW, Morson BC. The adenoma-carcinoma sequence. Major Probl Pathol. 1978; 10:58-71.
54. Jackman RJ, Mayo CW. The adenoma-carcinoma sequence in cancer of the colon. Surg Gynecol Obstet. 1951; 93(3):327-330.
55. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol. 2003; 119(6):778-796.
56. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst. 2001; 93(17):1307-1313. (Pubitemid 32910571)
57. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009; 4:343-364.
58. Vakiani E, Yantiss RK. Pathologic features and biologic importance of colorectal serrated polyps. Adv Anat Pathol. 2009; 16(2):79-91.
59. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol. 2007; 212(2):124-133. (Pubitemid 46852090)
60. Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology. 2006; 49(2):121-131. (Pubitemid 44079695)
61. Samowitz WS, Slattery ML. Microsatellite instability in colorectal adenomas. Gastroenterology. 1997,-112(5):1515-1519.
62. Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009; 11(3):238-247.
63. Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Cut. 1992; 33(6):783-786.
64. Messick CA, Church J, Casey G, Kalady MF. Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum. 2009; 52(9):1535-1541.